Pharmalittle: We’re reading about picking an FDA chief, a menopause film controversy, and more
President-elect Donald Trump will likely choose Johns Hopkins surgeon and writer Martin Makary to lead the FDA, sources say
Related Articles
Regulating generative AI: FDA’s limitations laid bare by digital health advisory committee
Generative AI poses unique challenges to the FDA’s regulatory process: from initial evaluation and review, to post market monitoring.
Rand Paul plans to investigate Covid-19 origins from his new perch leading a key committee
Paul is among the most vocal critics of the National Institutes of Health and former top infectious disease researcher Anthony Fauci
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer – Daniel Petrylak
David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs…
Payers Are Putting Profit Over Patients with Denials and Prior Auth Policies, Hospitals Say – MedCity News
Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. Hospital executives think federal regulators need to…
Home
Thursday, December 5, 2024 Thursday, December 12, 2024 Thursday, December 19, 2024 Credit Type CME,CNE,AAPA, AANP Intended Learners This activity is intended for primary care…
Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial – Alexander Chehrazi-Raffle
Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show…
Why whooping cough cases are spiking across the U.S.
Whooping cough cases haven’t been this high at this time of year since 2014, according to the CDC
FGFR3 Inhibition for Upper Tract Urothelial Cancer: Phase 1b Trial Results – Surena Matin
Sam Chang interviews Surena Matin about a phase 1b trial evaluating FGFR3 inhibition in localized upper tract urothelial carcinoma (UTUC). Dr. Matin discusses the study’s…
The FDA’s risky action on compounding weight loss drugs
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.
